Trial reportFrontiers in pediatrics2026
Inhaled budesonide and beclomethasone for the prevention and treatment of bronchopulmonary dysplasia in very preterm infants: a prospective randomized controlled trial.
Trial report in Frontiers in pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: To investigate the clinical efficacy and safety of inhaled budesonide and beclomethasone for the prevention and treatment of bronchopulmonary dysplasia (BPD) in very preterm infants. Methods: From October 2024 to November 2025, very preterm infants at high risk of BPD, aged >7 days and still requiring non-invasive respiratory support, who were admitted to the Neonatal Intensive Care Unit of Xuzhou Central Hospital, were selected and randomly divided into three groups. The control group received inhaled normal saline at a dose of 1 mL per administration, once every 12 h (q 12 h); the budesonide group received inhaled budesonide at a dose of 0.5 mg per administration, q 12 h; the beclomethasone group received inhaled beclomethasone at a dose of 0.4 mg per administration, q 12 h. Inhalation treatment was continued in all three groups until respiratory support was no longer needed. The total duration of respiratory support, the incidence and severity of BPD, the incidence of adverse outcomes, and inflammatory markers were compared among the three groups. Multivariate Logistic regression analysis was used to identify the independent risk factors and protective factors for BPD in very preterm infants. Results: Finally, 37 cases were enrolled in the control group, 41 cases in the budesonide group, and 40 cases in the beclomethasone group. The total duration of respiratory support and length of hospital stay in the budesonide group (36.4 ± 14.9 d, 39.5 ± 10.1 d) and the beclomethasone group (35.6 ± 15.1 d, 39.8 ± 11.0 d) were shorter than those in the control group (43.5 ± 13.5 d, 50.4 ± 8.5 d), with statistically significant differences ( Conclusions: Inhaled budesonide and beclomethasone after the first week of life can shorten the total duration of respiratory support in very preterm infants at high risk of BPD, aged > 7 days and still require non-invasive respiratory support, without increasing the incidence of adverse outcomes, demonstrating high safety. However, inhaled budesonide and beclomethasone do not show significant advantages in reducing the incidence and severity of BPD. Clinical Trial registration: https://www.chictr.org.cn/bin/project/edit?pid=248724, identifier ChiCTR2400091361.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.